EGFR negative

Gamma-camera imaging confirmed that [123I]I-(HE)3-E01-PIB demonstrated a higher imaging contrast in preclinical models than [99mTc]Tc-(HE)3-E01. In conclusion, DARPin (HE)3-E01 labeled using a non-residualizing [123I]I-para-iodobenzoate (PIB) label is the preferred radiotracer for in vivo imaging of EGFR expression in cancer.

Enhertu represents a promising treatment option for HER2-mutant metastatic lung cancer with recurrent brain metastasis. This case highlights the potential of Enhertu in overcoming treatment resistance in complex metastatic settings, warranting further investigation in broader clinical settings.

P2, N=62, Not yet recruiting, The First Affiliated Hospital of Guangzhou Medical University; The First Affiliated Hospital of Guangzhou Medical University

P2, N=69, Not yet recruiting, The Second Affiliated Hospital of Nanjing Medical University; The Second Affiliated Hospital of Nanjing Medical University

P=N/A, N=424, Recruiting, Shanghai Chest Hospital; Shanghai Chest Hospital | Not yet recruiting --> Recruiting

EGFR may serve as a potential prognostic marker and therapeutic target in TNBC. Further research with larger cohorts is recommended to validate these findings and explore the implications of EGFR-targeted therapies in TNBC management.

This study highlighted the effectiveness of multigene PCR testing in identifying actionable NSCLC biomarkers for low failure rate, short TAT, and minimal tissue requirements, enabling timely, personalized interventions. The workflow implemented at Chi Mei Medical Center provides a model that other hospitals can adopt to overcome testing barriers and improve precision oncology access.

No clear association was observed between HCMV in lung adenocarcinoma cells and the immune response to HCMV in peripheral blood, regardless of EGFR gene mutation status.

P2, N=117, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Sep 2025 --> Dec 2026 | Trial primary completion date: Sep 2025 --> Dec 2026

Although adjusted rwTTNT differed by treatment group, this did not translate to a significant difference in survival. Among mNSCLC patients with high PD-L1 expression, the addition of chemotherapy to ICI did not improve survival.

Our study highlights the aggressive nature of breast cancer in YBC aged <30 years, with relatively high rates of recurrence and mortality. Significant factors affecting prognosis may guide personalized treatment approaches and predict the prognosis.

Multifactorial regression analysis identified AR/ER ratio, histological classification, and lymph node metastasis as independent prognostic factors for DFS (all P < 0.05). The developed nomogram model underscored the significance of histological classification as the primary predictive factor for patient outcomes, followed by AR/ER ratio and lymph node metastasis AR expression holds varying prognostic implications across different breast cancer subtypes, with AR positivity indicating a favorable prognosis, particularly in ER-positive tumors.